Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
Rhea-AI Summary
Repligen (NASDAQ:RGEN) reported Q2 2026 revenue of $204 million, up 12% year-over-year as reported and 13% organically. GAAP income from operations was $14 million, flat year-over-year, while adjusted income from operations rose to $34 million from $22 million. GAAP diluted EPS was $0.09 versus $0.26, and adjusted diluted EPS increased to $0.54 from $0.37. GAAP gross margin was 53.9%, with adjusted operating margin improving to 16.7% from 12.0%. Cash, cash equivalents and marketable securities totaled $810 million at June 30, 2026.
For full-year 2026, Repligen now guides adjusted total revenue of $813–$835 million, implying 10–13% reported growth and 10.5–13.5% organic growth, adjusted operating margin of 15.7–16.0%, and adjusted diluted EPS of $2.03–$2.09. The company also announced a definitive agreement to acquire BioLife Solutions, intended to strengthen its cell therapy consumables platform.
Positive
- Q2 2026 revenue $204M, up 12% reported and 13% organic year-over-year
- Adjusted operating income $34M vs. $22M, up ~55% year-over-year
- Adjusted diluted EPS $0.54 vs. $0.37 in Q2 2025
- Adjusted operating margin 16.7% in Q2 2026 vs. 12.0% in Q2 2025
- Raised FY 2026 guidance: organic revenue growth 10.5–13.5%, EPS $2.03–$2.09
- Strong liquidity: $810M in cash, cash equivalents and marketable securities at June 30, 2026
Negative
- GAAP diluted EPS declined to $0.09 from $0.26 year-over-year in Q2
- GAAP net income margin fell to 2.5% from 8.2% in Q2 2025
- Operating expenses increased: SG&A $76.6M vs. $70.9M; R&D $14.4M vs. $14.0M
- Restructuring and other charges $2.7M in Q2 2026 vs. $2.2M in Q2 2025
- Six-month other income/expense swung to a $14.0M loss from $5.7M income, including a $13.7M loss on sale of business
News Explained
The updated FY26 guidance covers Repligen’s existing business and excludes the impact of potential or pending acquisitions, so it does not yet incorporate the announced BioLife Solutions transaction.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 05 | Q1 earnings report | Positive | +6.3% | Revenue growth, adjusted EPS increase and reiterated organic-growth guidance supported the quarterly update. |
| Feb 24 | Q4 earnings report | Positive | -0.5% | Full-year results and 2026 guidance accompanied a strong reported and organic growth profile. |
| Oct 28 | Q3 earnings report | Positive | -5.9% | Raised full-year guidance followed double-digit growth across franchises and record equipment placements. |
| Jul 29 | Q2 earnings report | Positive | +4.7% | Revenue growth, order momentum and higher full-year guidance characterized the quarterly release. |
| Apr 29 | Q1 earnings report | Positive | -2.9% | Revenue growth, acquisition completion and maintained guidance framed the quarterly results. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific earnings reactions were mixed, with 2 aligned positive responses and 3 divergences despite generally favorable announcements.
Key Terms
gaap financial
non-gaap financial
adjusted ebitda financial
organic revenue growth financial
fully diluted basis financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Second quarter revenue of
$204 million , a year-over-year increase of12% as reported and13% organic - GAAP operating income increased
1% year-over-year while adjusted operating income increased55% - Raising both FY26 organic revenue growth guidance to
10.5% -13.5% and adjusted EPS to$2.03 -$2.09
WALTHAM, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2026, covering the three-month period ended June 30, 2026. The Company is also providing updated financial guidance for the full year 2026.
Olivier Loeillot, President and Chief Executive Officer of Repligen said, “We were very pleased to deliver
Mr. Loeillot continued, “The announcement of our definitive agreement to acquire BioLife Solutions is a key milestone in our company’s journey. We believe this fast-tracks our cell therapy leadership, with a transaction that is accretive to our revenue growth, margin, and adjusted EPS.”
BUSINESS HIGHLIGHTS
- Announced Definitive Agreement to Acquire BioLife Solutions. The financially compelling transaction strengthens Repligen’s position in cell therapy by adding a differentiated, deeply embedded consumables platform with recurring revenue, commercial-stage exposure, and strong customer workflow integration.
- New Repligen Training & Innovation Center (“RTIC”). Opened a new RTIC at our OPUS® Pre-packed Chromatography Columns manufacturing facility in Breda, the Netherlands.
- 2025 Sustainability Report. Published our 2025 Sustainability Report “Driving Sustainable Growth Together”, highlighting the company’s progress across a range of initiatives supporting responsible business practices, workforce development, community engagement, and strong corporate governance.
FINANCIAL PERFORMANCE
Q2 2026 Financial Performance (compared to prior year periods except as noted)
All adjusted figures are non-GAAP and, except for earnings per share (“EPS”), are rounded to the nearest million, and are reconciled in the tables included later in this press release.
- Q2 reported revenue was
$204 million , compared to$182 million , an increase of12% as reported and13% organic. - GAAP Results. Q2 income from operations was
$14 million , compared to$14 million . Q2 EPS was$0.09 on a fully diluted basis, compared to$0.26 . - Adjusted Results. Q2 adjusted income from operations was
$34 million , compared to$22 million . Q2 adjusted EPS was$0.54 on a fully diluted basis, compared to$0.37 .
MARGIN SUMMARY
| GAAP Margins | Q2 2026 | Q2 2025 | Q2-YTD 2026 | Q2-YTD 2025 | ||||
| Gross Margin | ||||||||
| Operating (EBIT) Margin | ||||||||
| Net Income Margin | ||||||||
| Adjusted (non-GAAP) Margins | Q2 2026 | Q2 2025 | Q2-YTD 2026 | Q2-YTD 2025 | ||||
| Gross Margin | ||||||||
| Operating (EBIT) Margin | ||||||||
| Net Income Margin | ||||||||
| EBITDA Margin | ||||||||
Cash, cash equivalents and marketable securities at June 30, 2026, were
FINANCIAL GUIDANCE FOR FULL YEAR 2026
All adjusted figures are non-GAAP
Our financial guidance for the full year 2026 is based on expectations for our existing business. Our Adjusted (non-GAAP) guidance excludes the impact of any potential or pending business acquisitions in 2026, and future fluctuations in foreign currency exchange rates.
| CURRENT GUIDANCE | ||
| (at July 28, 2026) | ||
| FY 2026 | Adjusted (non-GAAP) | |
| Total Reported Revenue | ||
| Reported Growth | ||
| Organic Growth | ||
| Gross Margin | ||
| Income from Operations | ||
| Operating Margin | ||
| Other Income (Expense) | ~ | |
| Adjusted EBITDA Margin | ||
| Tax Rate on Pre-Tax Income | ~ | |
| Net Income | ||
| Earnings Per Share - Diluted | ||
Total reported revenue guidance reflects less than 50 basis points of benefit from foreign currency and approximately one-point headwind primarily from the divestiture of Polymem.
Conference Call and Webcast Access
Repligen will host a conference call and webcast today, July 28, 2026, at 8:00 a.m. ET, to discuss second quarter 2026 financial results, corporate developments and financial guidance for 2026. The conference call will be accessible by dialing toll-free (833) 461-5787 for domestic callers and (585) 542-9983 for international callers. The meeting ID is: 768981187. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. The webcast will be archived for a period of time following the live event. You can access the replay on the Investor Relations section of the Company’s website.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information about the Company see our website at www.repligen.com, and follow us on LinkedIn.
Non-GAAP Measures of Financial Performance
To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (“GAAP”), the following Adjusted (“non-GAAP”) measures of financial performance are included in this release: organic revenue and organic revenue growth; adjusted gross profit and adjusted gross margin; adjusted income from operations and adjusted operating margin; organic adjusted operating margin year-over-year change; adjusted net income and adjusted net income margin; adjusted earnings per share (diluted); adjusted earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA margin. The Company provides the impact of foreign currency translation, to enable determination of revenue and margin growth rates at constant currency. To calculate the impact of foreign currency translation, the Company converts the reported amounts from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior year periods.
The Company’s non-GAAP financial results and/or non-GAAP guidance exclude the impact of: acquisition, integration and divestiture costs; restructuring charges including the costs of severance and accelerated depreciation among other non-cash charges; inventory step-up costs and adjustments; transformation costs including incremental, non-recurring expenses for discrete strategic projects that are designed to deliver long-term benefits, including improvements to enhance productivity and enable company growth that do not meet the definition of restructuring; contingent consideration related to the Company’s acquisitions; intangible amortization costs; non-cash interest expense related to the accretion of the debt discount; amortization of debt issuance costs related to Company’s convertible debt; foreign currency impact of certain intercompany loans; loss on sale of business; and, the related impact on tax of non-GAAP charges.
These costs are excluded because management believes that such expenses do not have a direct correlation to future business operations, nor do the resulting charges recorded accurately reflect the performance of our ongoing operations for the period in which such charges are recorded. Additionally, for a project to be considered transformational, the project expenses are expected to bring long-term growth, profitability improvements and defined process and technology improvements. Our transformation initiative is multi-year but each project has a discrete, defined timeline. Further, organic adjusted operating margin year-over-year change excludes the effect of adjustments above, as well as the impact of mergers, acquisitions and divestitures and foreign exchange. This measure is used by the Company in periods of acquisition because the timing, size and number of such transactions and their related impact on the financial statements may vary and make comparison of long-term results difficult.
All reconciliations of above GAAP figures to adjusted (non-GAAP) figures are detailed in the tables included later in this press release. Certain prior year amounts have been reclassified to conform with the current year presentation. When analyzing the Company’s operating performance and guidance, investors should not consider non-GAAP measures as a substitute for the comparable financial measures prepared in accordance with GAAP.
The Company does not provide GAAP financial measures on a forward-looking basis as the Company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort. The Company cannot reasonably predict items including, but not limited to, the timing and amount of future restructuring and cost-savings actions or transformation, acquisition and integration related costs. These items are generally uncertain and are not indicative of ongoing operations of the business, and the impact could be material to our results in accordance with GAAP.
Forward-Looking Statements
This press release contains forward-looking statements, which are made pursuant to and in reliance upon the safe harbor provisions of federal securities laws, including the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained herein which do not describe historical facts, including, among others, any express or implied statements or guidance regarding current or future financial performance and position, including our 2026 financial guidance and related assumptions; expected demand in the markets in which we operate; and the expected performance of our business and momentum across our portfolio, are based on management’s current expectations and beliefs and are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.
Such risks and uncertainties include, among others, our ability to successfully grow our bioprocessing business; our ability to manage through and predict headwinds; the risk that we have assumed that markets and franchises will improve and grow as predicted; our ability to achieve our 2026 financial guidance; our ability to develop and commercialize products and the market acceptance of our products; our ability to complete the proposed acquisition of BioLife Solutions, including the anticipated timing and completion of the transaction, the expected benefits and synergies of the transaction, the ability to integrate the businesses, and the Company’s expectations regarding the future performance of the combined company; our ability to successfully integrate any acquired businesses and relevant personnel in a timely manner or at all, and to achieve the expected benefits of such acquisitions; the risk that demand for our products could decline, which could adversely impact our future revenues, cash flows, results of operations and financial condition; our ability to compete with larger, better financed bioprocessing companies; risks around the Company’s effectiveness of disclosure controls and procedures and the effectiveness of our internal control over financial reporting; our compliance with all U.S. Food and Drug Administration and European Medicines Evaluation Agency regulations; our volatile stock price; the impact of tariffs on our business, and other risks and uncertainties detailed in Repligen’s filings with the U.S. Securities and Exchange Commission (the Commission), including our Annual Report on Form 10-K for the year ended December 31, 2025 and in subsequently filed reports with the Commission, including our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any subsequent filings made with the Commission, which are available at the Commission’s website at www.sec.gov. Actual results may differ materially from those Repligen contemplated by these forward-looking statements, which reflect management’s current views, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions, and are based only on information currently available to us. Repligen cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Repligen disclaims any obligation to update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
Repligen Contact:
Jacob Johnson
VP, Investor Relations
(781) 419-0204
investors@repligen.com
| REPLIGEN CORPORATION | ||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
| (Unaudited, amounts in thousands, except share data) | ||||||||
| June 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 606,783 | $ | 566,021 | ||||
| Marketable securities | 203,666 | 201,607 | ||||||
| Accounts receivable, net of allowances of | 157,710 | 158,587 | ||||||
| Inventories, net | 186,604 | 170,458 | ||||||
| Prepaid expenses and other current assets | 45,791 | 40,712 | ||||||
| Total current assets | 1,200,554 | 1,137,385 | ||||||
| Property, plant and equipment, net | 167,513 | 186,614 | ||||||
| Intangible assets, net | 357,622 | 386,147 | ||||||
| Goodwill | 1,104,183 | 1,114,408 | ||||||
| Deferred tax assets | 700 | 694 | ||||||
| Operating lease right of use assets | 115,559 | 119,538 | ||||||
| Other noncurrent assets | 4,049 | 4,913 | ||||||
| Total assets | $ | 2,950,180 | $ | 2,949,699 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 33,233 | $ | 30,010 | ||||
| Operating lease liabilities | 19,318 | 21,559 | ||||||
| Contingent consideration | 3,025 | 5,049 | ||||||
| Accrued liabilities | 77,080 | 79,208 | ||||||
| Total current liabilities | 132,656 | 135,826 | ||||||
| Convertible Senior Notes due 2028, net | 551,046 | 542,213 | ||||||
| Deferred tax liabilities | 16,778 | 22,496 | ||||||
| Noncurrent operating lease liabilities | 120,578 | 126,176 | ||||||
| Noncurrent contingent consideration | — | 1,304 | ||||||
| Other noncurrent liabilities | 17,090 | 15,555 | ||||||
| Total liabilities | 838,148 | 843,570 | ||||||
| Stockholders' equity: | ||||||||
| Preferred stock, | — | — | ||||||
| Common stock, | 564 | 563 | ||||||
| Additional paid-in capital | 1,661,665 | 1,651,849 | ||||||
| Accumulated other comprehensive loss | (19,786 | ) | (2,531 | ) | ||||
| Retained earnings | 469,589 | 456,248 | ||||||
| Total stockholders’ equity | 2,112,032 | 2,106,129 | ||||||
| Total liabilities and stockholders’ equity | $ | 2,950,180 | $ | 2,949,699 | ||||
| REPLIGEN CORPORATION | ||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
| (Unaudited, amounts in thousands, except per share data) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue: | ||||||||||||||||
| Product | $ | 204,085 | $ | 182,329 | $ | 398,296 | $ | 351,466 | ||||||||
| Royalty and other revenue | 43 | 37 | 87 | 72 | ||||||||||||
| Total revenue | 204,128 | 182,366 | 398,383 | 351,538 | ||||||||||||
| Costs and operating expenses: | ||||||||||||||||
| Cost of goods sold | 94,091 | 89,371 | 180,062 | 167,172 | ||||||||||||
| Research and development | 14,417 | 13,970 | 28,875 | 26,084 | ||||||||||||
| Selling, general and administrative | 76,618 | 70,906 | 153,154 | 141,612 | ||||||||||||
| Restructuring activities and other charges | 2,718 | 2,162 | 4,214 | 4,135 | ||||||||||||
| Change in fair value of contingent consideration | 2,308 | (7,939 | ) | 2,162 | (7,939 | ) | ||||||||||
| Total costs and operating expenses | 190,152 | 168,470 | 368,467 | 331,064 | ||||||||||||
| Income from operations | 13,976 | 13,896 | 29,916 | 20,474 | ||||||||||||
| Other income (expense), net: | ||||||||||||||||
| Investment income | 6,431 | 6,585 | 12,773 | 13,899 | ||||||||||||
| Interest expense | (5,663 | ) | (5,354 | ) | (11,241 | ) | (10,604 | ) | ||||||||
| Amortization of debt issuance costs | (421 | ) | (414 | ) | (840 | ) | (827 | ) | ||||||||
| Loss on sale of business | 103 | — | (13,660 | ) | — | |||||||||||
| Other (expense) income, net | (273 | ) | 3,502 | (1,023 | ) | 3,216 | ||||||||||
| Other income (expense), net | 177 | 4,319 | (13,991 | ) | 5,684 | |||||||||||
| Income before income taxes | 14,153 | 18,215 | 15,925 | 26,158 | ||||||||||||
| Income tax provision | 9,145 | 3,349 | 2,584 | 5,462 | ||||||||||||
| Net income | $ | 5,008 | $ | 14,866 | $ | 13,341 | $ | 20,696 | ||||||||
| Earnings per share: | ||||||||||||||||
| Basic | $ | 0.09 | $ | 0.26 | $ | 0.24 | $ | 0.37 | ||||||||
| Diluted | $ | 0.09 | $ | 0.26 | $ | 0.24 | $ | 0.37 | ||||||||
| Weighted average common shares outstanding: | ||||||||||||||||
| Basic | 56,418 | 56,234 | 56,387 | 56,179 | ||||||||||||
| Diluted | 56,638 | 56,510 | 56,661 | 56,509 | ||||||||||||
| REPLIGEN CORPORATION | ||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
| (Unaudited, amounts in thousands) | ||||||||
| Six Months Ended June 30, | ||||||||
| 2026 | 2025 | |||||||
| Cash flows from operating activities | ||||||||
| Net income | $ | 13,341 | $ | 20,696 | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 38,824 | 38,785 | ||||||
| Amortization of debt discount and issuance costs | 8,833 | 8,158 | ||||||
| Loss on sale of business | 13,660 | — | ||||||
| Stock-based compensation | 16,335 | 15,648 | ||||||
| Deferred income taxes, net | (4,775 | ) | (2,569 | ) | ||||
| Change in fair value of contingent consideration | 2,162 | (7,939 | ) | |||||
| Net unrealized foreign exchange gain | (119 | ) | (12,253 | ) | ||||
| Operating lease right of use asset amortization | 9,486 | 9,169 | ||||||
| Other adjustments and non-cash items | (1,815 | ) | 12,444 | |||||
| Changes in operating assets and liabilities, excluding impact of acquisitions: | ||||||||
| Accounts receivable | (4,362 | ) | (15,158 | ) | ||||
| Inventories | (20,158 | ) | (824 | ) | ||||
| Prepaid expenses and other current assets | (5,962 | ) | (176 | ) | ||||
| Other noncurrent assets | 1,894 | (1,547 | ) | |||||
| Accounts payable | 6,112 | (8,277 | ) | |||||
| Accrued liabilities | (527 | ) | (2,995 | ) | ||||
| Operating lease liabilities | (13,358 | ) | (9,804 | ) | ||||
| Noncurrent liabilities | 1,490 | 256 | ||||||
| Total cash provided by operating activities | 61,061 | 43,614 | ||||||
| Cash flows for investing activities | ||||||||
| Acquisitions, net of cash acquired | — | (69,954 | ) | |||||
| Divestiture proceeds, net of cash divested | 3,637 | — | ||||||
| Purchases of marketable securities | (130,698 | ) | — | |||||
| Maturities of marketable securities | 132,000 | — | ||||||
| Additions to capitalized software costs | (972 | ) | (1,371 | ) | ||||
| Purchases of property, plant and equipment | (10,044 | ) | (10,664 | ) | ||||
| Sale of property, plant and equipment | — | 42 | ||||||
| Total cash used in investing activities | (6,077 | ) | (81,947 | ) | ||||
| Cash flows for financing activities | ||||||||
| Proceeds from exercise of stock options | 94 | 1,464 | ||||||
| Payment of tax withholding obligation on vesting of restricted stock | (6,612 | ) | (7,170 | ) | ||||
| Payment of earnout consideration | (5,225 | ) | (9,455 | ) | ||||
| Total cash used in financing activities | (11,743 | ) | (15,161 | ) | ||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (456 | ) | 4,994 | |||||
| Net increase (decrease) in cash, cash equivalents and restricted cash | 42,785 | (48,500 | ) | |||||
| Cash, cash equivalents and restricted cash, beginning of period | $ | 566,021 | $ | 757,355 | ||||
| Cash, cash equivalents and restricted cash, end of period | $ | 608,806 | $ | 708,855 | ||||
RECONCILIATIONS OF GAAP TO NON-GAAP FINANCIAL MEASURES
(Unaudited, amounts in thousands, except percentage and earnings per share data)
In all tables below, totals may not add due to rounding
Reconciliation of Total Revenue (GAAP) Growth to Organic Revenue Growth (Non-GAAP)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| TOTAL REPORTED REVENUE (GAAP) GROWTH | 12 | % | 15 | % | 13 | % | 13 | % | ||||||||
| Acquisition and divestiture revenue | 1 | % | (2 | )% | 1 | % | (1 | )% | ||||||||
| Currency exchange | 0 | % | (2 | )% | (1 | )% | 0 | % | ||||||||
| ORGANIC REVENUE GROWTH (NON-GAAP) | 13 | % | 11 | % | 12 | % | 11 | % | ||||||||
Reconciliation of Income from Operations (GAAP) to Adjusted Income from Operations (Non-GAAP)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| INCOME FROM OPERATIONS (GAAP) | $ | 13,976 | $ | 13,896 | $ | 29,916 | $ | 20,474 | ||||||||
| ADJUSTMENTS TO INCOME FROM OPERATIONS (GAAP): | ||||||||||||||||
| Acquisition, integration and divestiture costs | 2,127 | 4,282 | 4,818 | 10,315 | ||||||||||||
| Restructuring activities and other charges(1) | 2,718 | 2,198 | 4,214 | 4,171 | ||||||||||||
| Transformation costs(2) | 2,949 | (1,409 | ) | 3,078 | (2,293 | ) | ||||||||||
| Intangible amortization | 9,547 | 10,204 | 19,341 | 19,325 | ||||||||||||
| Contingent Consideration | 2,308 | (7,939 | ) | 2,162 | (7,939 | ) | ||||||||||
| Inventory step-up charges | — | 577 | — | 577 | ||||||||||||
| Other(4) | 379 | 102 | 379 | 686 | ||||||||||||
| ADJUSTED INCOME FROM OPERATIONS (NON-GAAP) | $ | 34,004 | $ | 21,911 | $ | 63,908 | $ | 45,316 | ||||||||
| OPERATING (EBIT) MARGIN (GAAP) | 6.8 | % | 7.6 | % | 7.5 | % | 5.8 | % | ||||||||
| ADJUSTED OPERATING (EBIT) MARGIN (NON-GAAP) | 16.7 | % | 12.0 | % | 16.0 | % | 12.9 | % | ||||||||
Reconciliation of Operating (EBIT) Margin Growth to Organic Adjusted Operating Margin Growth (Non-GAAP)
| Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 | |||||||
| OPERATING (EBIT) MARGIN (GAAP) YEAR-OVER-YEAR CHANGE | (0.8 | )% | 1.7 | % | ||||
| Acquisition, integration and divestiture costs | (1.3 | )% | (1.7 | )% | ||||
| Restructuring activities and other charges(1) | 0.1 | % | (0.1 | )% | ||||
| Transformation costs(2) | 2.2 | % | 1.4 | % | ||||
| Intangible amortization | (0.9 | )% | (0.6 | )% | ||||
| Contingent Consideration | 5.5 | % | 2.8 | % | ||||
| Inventory step-up charges | (0.3 | )% | (0.2 | )% | ||||
| Other(4) | 0.1 | % | (0.1 | )% | ||||
| ADJUSTED OPERATING (EBIT) MARGIN (NON-GAAP) YEAR-OVER-YEAR CHANGE | 4.6 | % | 3.2 | % | ||||
| Impact of mergers, acquisitions, and divestitures | (0.4 | )% | 0.5 | % | ||||
| Currency exchange | (0.1 | )% | (0.4 | )% | ||||
| ORGANIC ADJUSTED OPERATING MARGIN (NON-GAAP) YEAR-OVER-YEAR CHANGE | 4.1 | % | 3.3 | % | ||||
Reconciliation of Net Income (GAAP) to Adjusted Net Income (Non-GAAP)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| NET INCOME (GAAP) | $ | 5,008 | $ | 14,866 | $ | 13,341 | $ | 20,696 | ||||||||
| ADJUSTMENTS TO NET INCOME (GAAP): | ||||||||||||||||
| Acquisition, integration and divestiture costs | 2,127 | 4,282 | 4,818 | 10,315 | ||||||||||||
| Restructuring activities and other charges(1) | 2,718 | 2,198 | 4,214 | 4,171 | ||||||||||||
| Transformation costs(2) | 2,949 | (1,409 | ) | 3,078 | (2,293 | ) | ||||||||||
| Intangible amortization | 9,547 | 10,204 | 19,341 | 19,325 | ||||||||||||
| Contingent Consideration | 2,212 | (11,053 | ) | 2,064 | (11,053 | ) | ||||||||||
| Inventory step-up charges | — | 577 | — | 577 | ||||||||||||
| Non-cash interest expense | 4,161 | 3,827 | 8,235 | 7,574 | ||||||||||||
| Amortization of debt issuance costs | 421 | 414 | 840 | 827 | ||||||||||||
| Foreign currency impact of certain intercompany loans(3) | 618 | — | 1,508 | — | ||||||||||||
| Loss on sale of business | (103 | ) | — | 13,660 | — | |||||||||||
| Other(4) | 379 | 102 | 379 | 686 | ||||||||||||
| Tax effect of non-GAAP charges | 740 | (2,853 | ) | (13,547 | ) | (7,429 | ) | |||||||||
| ADJUSTED NET INCOME (NON-GAAP) | $ | 30,777 | $ | 21,155 | $ | 57,931 | $ | 43,396 | ||||||||
| NET INCOME MARGIN (GAAP) | 2.5 | % | 8.2 | % | 3.3 | % | 5.9 | % | ||||||||
| ADJUSTED NET INCOME MARGIN (NON-GAAP) | 15.1 | % | 11.6 | % | 14.5 | % | 12.3 | % | ||||||||
Reconciliation of EPS (GAAP) to EPS (Non-GAAP)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| EPS (GAAP) - DILUTED | $ | 0.09 | $ | 0.26 | $ | 0.24 | $ | 0.37 | ||||||||
| ADJUSTMENTS TO EPS (GAAP) - DILUTED: | ||||||||||||||||
| Acquisition, integration and divestiture costs | 0.04 | 0.08 | 0.09 | 0.18 | ||||||||||||
| Restructuring activities and other charges(1) | 0.05 | 0.04 | 0.07 | 0.07 | ||||||||||||
| Transformation costs(2) | 0.05 | (0.02 | ) | 0.05 | (0.04 | ) | ||||||||||
| Intangible amortization | 0.17 | 0.18 | 0.34 | 0.34 | ||||||||||||
| Contingent Consideration | 0.04 | (0.20 | ) | 0.04 | (0.20 | ) | ||||||||||
| Inventory step-up charges | — | 0.01 | — | 0.01 | ||||||||||||
| Non-cash interest expense | 0.07 | 0.07 | 0.15 | 0.13 | ||||||||||||
| Amortization of debt issuance costs | 0.01 | 0.01 | 0.01 | 0.01 | ||||||||||||
| Foreign currency impact of certain intercompany loans(3) | 0.01 | — | 0.03 | — | ||||||||||||
| Loss on sale of business | (0.00 | ) | — | 0.24 | — | |||||||||||
| Other(4) | 0.01 | 0.00 | 0.01 | 0.01 | ||||||||||||
| Tax effect of non-GAAP charges | 0.01 | (0.05 | ) | (0.24 | ) | (0.13 | ) | |||||||||
| ADJUSTED EPS (NON-GAAP) - DILUTED | $ | 0.54 | $ | 0.37 | $ | 1.02 | $ | 0.77 | ||||||||
Reconciliation of Net Income (GAAP) to Adjusted EBITDA (Non-GAAP)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| NET INCOME (GAAP) | $ | 5,008 | $ | 14,866 | $ | 13,341 | $ | 20,696 | ||||||||
| ADJUSTMENTS: | ||||||||||||||||
| Investment income | (6,431 | ) | (6,585 | ) | (12,773 | ) | (13,899 | ) | ||||||||
| Interest expense | 5,663 | 5,354 | 11,241 | 10,604 | ||||||||||||
| Amortization of debt issuance costs | 421 | 414 | 840 | 827 | ||||||||||||
| Income tax (benefit) provision | 9,145 | 3,349 | 2,584 | 5,462 | ||||||||||||
| Depreciation | 9,515 | 9,850 | 19,483 | 19,405 | ||||||||||||
| Intangible amortization | 9,547 | 10,231 | 19,341 | 19,380 | ||||||||||||
| EBITDA (NON-GAAP) | $ | 32,868 | $ | 37,479 | $ | 54,057 | $ | 62,475 | ||||||||
| OTHER ADJUSTMENTS: | ||||||||||||||||
| Acquisition, integration and divestiture costs | 2,127 | 4,282 | 4,818 | 10,315 | ||||||||||||
| Restructuring activities and other charges(1) | 2,718 | 2,198 | 4,214 | 4,171 | ||||||||||||
| Transformation costs(2) | 2,949 | (1,409 | ) | 3,078 | (2,293 | ) | ||||||||||
| Contingent Consideration | 2,212 | (11,053 | ) | 2,064 | (11,053 | ) | ||||||||||
| Inventory step-up charges | — | 577 | — | 577 | ||||||||||||
| Foreign currency impact of certain intercompany loans(3) | 618 | — | 1,508 | — | ||||||||||||
| Loss on sale of business | (103 | ) | — | 13,660 | — | |||||||||||
| Other(4) | 379 | 102 | 379 | 686 | ||||||||||||
| ADJUSTED EBITDA (NON-GAAP) | $ | 43,768 | $ | 32,176 | $ | 83,778 | $ | 64,878 | ||||||||
| NET INCOME MARGIN (GAAP) | 2.5 | % | 8.2 | % | 3.3 | % | 5.9 | % | ||||||||
| ADJUSTED EBITDA MARGIN (NON-GAAP) | 21.4 | % | 17.6 | % | 21.0 | % | 18.5 | % | ||||||||
| FOOTNOTES FOR ALL TABLES ABOVE: | |
| (1) | Restructuring activities and other charges includes the costs of severance and accelerated depreciation among other non-cash charges. Charges for the three and six months ended June 30, 2026, consists of activities to simplify the global manufacturing footprint of the organization and align its workforce to support long-term company growth. |
| (2) | For the three and six months ended June 30, 2026, transformation costs include |
| (3) | During the three and six months ended June 30, 2026 we recorded foreign currency losses on certain intercompany loans of |
| (4) | Other charges for the three and six months ended June 30, 2026 includes other expenses that are non-indicative of our ongoing performance. The three and six months ended June 30, 2025 includes charges related to one-time events relating to a cybersecurity incident, net of insurance, and costs associated with the restatement of previously issued financial statements. |
